BioCatalystWatch
KAPAWorkspace / KAPA / OverviewCompany library
Price
Market cap
Next catalystJun 4 - Dec 31, 2026CL-741 · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

CL-741

c-MET

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

CL-741

c-MET

Upcoming / outlook

Other pipelines

ENV-205

PreINDP1P2P3FilingApproved
KROS-401

IL-4/IL-13 receptor complex

PreINDP1P2P3FilingApproved
ENV-105

CD105

PreINDP1P2P3FilingApproved
KROS-201

IND

PreINDP1P2P3FilingApproved
KROS-741

cMET

PreINDP1P2P3FilingApproved
KROS-101

GITR ligand

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

KAPA PR & News

PR & News

KAPA SEC archive